Fetalix has been highlighted by Tanya Ridding, LinkedIn Top Voice and Global Director at Invenia Group, as one of Portugal’s most promising early-stage MedTech startups during LSI Europe 2024.
The feature placed Fetalix among a select group of ten innovative Portuguese MedTech startups advancing healthcare technologies across areas such as diagnostics, digital health, rehabilitation, and neurotechnology. The selection reflects growing international attention to Portugal’s emerging innovation ecosystem and its role in developing next-generation healthcare solutions.
External recognition from experienced industry leaders plays an important role in early-stage biotechnology, as it provides independent validation of a company’s technological relevance, market potential, and positioning within the global MedTech landscape.
This acknowledgement reinforces Fetalix’s visibility within the international innovation ecosystem and supports its positioning as a science-driven company developing regenerative solutions for intervertebral disc degeneration and low back pain.
October 1, 2024
